UNH vs UTHR

UnitedHealth Group (UNH) remains a robust, high-quality mega-cap in the mature and highly regulated healthcare sector. Q1 2026 adjusted EPS of $7.23, a recent dividend increase to $2.32, and some analyst upgrades (e.g., Truist to $440, Goldman Sachs Conviction Buy) reflect solid operational performance and financial strength. However, these are characteristics of a stable compounder, not a company...

United Therapeutics continues to present a compelling long-term narrative driven by its robust pipeline, particularly with the positive Phase 3 results for Ralinepag and Tyvaso nebulized treprostinil, expanding its addressable markets in pulmonary hypertension and idiopathic pulmonary fibrosis. The company maintains a strong balance sheet with healthy cash flow generation. However, achieving a 10x...